It is reported that the first China chs-drg / Dip payment reform conference was held in Beijing recently, and the national medical insurance bureau announced the official launch of the three-year action plan for DRG / Dip payment reform. According to the three-year action plan for DRG / Dip payment reform issued, by the end of 2024, all overall planning areas in China will carry out DRG / Dip payment reform. By the end of 2025, DRG / Dip payment will cover all qualified medical institutions carrying out inpatient services.
Tianfeng Securities Co.Ltd(601162) pointed out that the national medical security administration and others recently held the first China Conference on the reform of payment methods by disease diagnosis related grouping (chs-drg) and by disease score (DIP). We believe that products and services with efficiency improvement and cost control will benefit. After DRG, hospitals have strong motivation to improve operation and management efficiency, including carrying out more projects with advantages of hospitals and improving cost management ability. In terms of investment, investment opportunities can be sought from the following three dimensions:
1、 Help hospitals improve efficiency. Under the DRG mode, the hospital has a strong motivation to carry out projects more in line with its own cost and technical advantages, which can help the hospital improve its operation turnover efficiency (especially shorten the number of inpatient bed days and reduce the time consumption index and cost consumption index). For example, the proportion of minimally invasive surgery or daytime surgery is expected to continue to increase, and the rehabilitation private medical institutions will also get better business opportunities, Related products and drugs will also benefit. Main companies and products: Ningbo Sanxing Medical Electric Co.Ltd(601567) , anesthesia products, minimally invasive products.
2、 Help hospitals control costs. After the DRG grouping is determined, the hospital has a strong motivation to use more cost-effective products or strengthen product management to reduce costs (reduce drug consumption index and sanitary material consumption index). The main companies are: Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , Micro-Tech (Nanjing) Co.Ltd(688029) , Apt Medical Inc(688617) , Shandong Weigao Orthopaedic Device Co.Ltd(688161) , guichuangtong bridge, Qingdao Haier Biomedical Co.Ltd(688139) .
3、 Help hospitals enhance it capabilities. DRG has high requirements for hospital management system, including data collection and analysis, information management, etc., so medical information related companies will benefit.
(Securities Times)
